VIVIMED LABS LIMITED
Latest filings
- Vivimed Labs 7th CoC meeting scheduled for September 10, 2026 · Regulatory & Legal
- Vivimed Labs 6th Committee of Creditors meeting on August 18, 2026 · Regulatory & Legal
- NSE seeks clarification from Vivimed Labs on Dec-2025 quarter results · Regulatory & Legal
- Vivimed Labs reports nil re-lodgement transfer requests for June 2026 · Compliance
- Vivimed Labs submits newspaper ad for March 2026 results · Compliance
- Vivimed Labs reports huge FY26 loss, under insolvency process · Results
- Board meeting on 17 July 2026 to approve FY26 audited results · Results
- Vivimed Labs files quarterly dematerialisation compliance certificate · Compliance
- RTA compliance certificate for share dematerialization Q1 FY27 · Compliance
- Trading window closed from July 1 ahead of Q1 FY27 results · Compliance
- Trading window closure for Q1 FY27 results · Compliance
- Vivimed Labs clarifies NSE queries on FY25 results filing · Regulatory & Legal
- Promoters confirm no share encumbrance created in FY26 · Ownership Changes
- Vivimed Labs publishes Form G for CIRP resolution applicants · Regulatory & Legal
- Vivimed Labs under insolvency, invites resolution bids · Regulatory & Legal
- Vivimed Labs Limited has informed the Exchange regarding 'Board meeting postponed'. · Board & Shareholder Meetings
- Board meeting Postponed · Board & Shareholder Meetings
- The Board Meeting to be held on 28/05/2026 has been revised to 30/05/2026 The Board Meeting to be held on 28/05/2026 has been revised to 30/05/2026 · Results
- Vivimed Labs Limited has informed the Exchange regarding 'Annual secretarial compliance report'. · Compliance
- annual secretarial compliance report · Compliance
- Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2026 ,inter alia, to consider and approve audited results for FY 2025-2026 · Results
- Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process · Regulatory & Legal
- Vivimed Labs admitted to insolvency resolution by NCLT · Regulatory & Legal
- Vivimed Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Vivimed Labs Limited has informed the Exchange regarding 'Not Large Corporate'. · Compliance
- Trading Window Closure for Q4 FY26 Financial Results · Compliance
- Vivimed Labs Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025. · Results
- Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/03/2026 ,inter alia, to consider and approve Notice of Board meeting · Results
- updates (additional information) · Regulatory & Legal
- Vivimed Labs Limited has informed the Exchange about Corporate Insolvency Resolution Process · Regulatory & Legal
- The Board Meeting to be held on 13/02/2026 Stands Cancelled. · Results
- Vivimed Labs Limited has informed regarding Disclosure of material issue · Regulatory & Legal
- Vivimed Labs Limited has informed regarding Disclosure of material issue · Regulatory & Legal
- Vivimed Labs Limited has informed regarding Disclosure of material issue · Regulatory & Legal
- Vivimed Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 ,inter alia, to consider and approve 31st december 2025 results · Results
- Vivimed Labs Limited has informed the Exchange about General Updates · Compliance
- The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited. · Regulatory & Legal
- Vivimed Labs Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 · Compliance
- Significant movement in price has been observed in Vivimed Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Vivimed Labs Limited has submitted their response. · Regulatory & Legal
- Significant movement in price has been observed in Vivimed Labs Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited. · Regulatory & Legal
- Vivimed Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 · Compliance
- Revocation of Suspension in Trading of Equity Shares of Vivimed Labs LimitedWe are delighted to inform both exchanges, our valued shareholders, and market participants that BSE Limited and the National Stock Exchange of India Limited (NSE) have officially communicated their decision to revoke the suspension in trading of equity shares of Vivimed Labs Limited. As per the notifications received:Date of Circular/Notice: December 10, 2025Effective Date of Revocation: Trading in equity shares will resume from December 18, 2025.This revocation marks a significant turning point, reinstating liquidity and enabling price discovery for our shareholders. The Company has diligently complied with all requisite regulatory norms, specifically addressing previous non-compliances under SEBI (LODR) Regulations, 2015. We assure you that we will continue in the same spirit for the years to come.We extend our sincere gratitude to both exchanges and our shareholders for their unwavering support and patience throughout this challenging period.We look forward to commencing trading with renewed vigor and commitment to transparency, growth, and sustained shareholder value.The official circulars detailing this revocation are available on the websites of BSE and NSE for further reference.(attached) · Capital Market Events
- Vivimed Labs Limited has submitted the Exchange a copy Srutinizers report of undefined held on December 10, 2025 · Compliance
- Vivimed Labs Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on December 10, 2025 · Board & Shareholder Meetings
- Vivimed Labs Limited has informed the Exchange about General Updates Post dispatch of Notice of EGM Newspaper add · Compliance
- Vivimed Labs Limited has informed the Exchange about General Updates Pre dispatch of Notice of EGM Newspaper add · Compliance
- Vivimed Labs Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on December 10, 2025 · Board & Shareholder Meetings
- Vivimed Labs Limited has informed the Exchange about General Updates · General
- Vivimed Labs Limited has informed the Exchange regarding 'ResultsH12026'. · Results
- Vivimed Labs Limited has informed the Exchange about General Updates · General
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical dosages at four plants in Hyderabad, Haridwar, Kashipur, and Bidar, with 352 employees reported as part of the insolvency filings. Standalone FY25 revenue is reported at ₹116.269 crore, while a related filing cited FY25 revenue of ₹103.6 crore against ₹136.8 crore in FY24; standalone revenue for the nine months ended December 2025 was ₹48.23 crore. The cost structure is materials-heavy at 49.7% of revenue, followed by employee costs at 24.4% and other opex at 34.9% of revenue. The NCLT Bengaluru Bench admitted the company into Corporate Insolvency Resolution Process on April 15, 2026, following a petition by Blue Cube Germany Assets GmbH, an operational creditor, for unpaid debt of ₹32.79 crore from chemical supplies made in 2012-2014. The board has been suspended, an Interim Resolution Professional has been appointed, and a CBI investigation is pending; the statutory auditor has flagged going-concern uncertainty, unrecorded interest of ₹626 million, and confirmed that all loans are non-performing assets.
Scorecard
Measured from the filed financials · as of FY25 — not investment advice
Strengths
Nothing stands out in the filed numbers.Concerns
Charts
How has the market priced it — with filings on the timeline?
VIVIMEDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from VIVIMED LABS LIMITED's filed financials and exchange disclosures
What does VIVIMED LABS LIMITED do?
VIVIMED LABS LIMITED is listed on NSE and BSE, trading under the symbol VIVIMEDLAB.
Is VIVIMED LABS LIMITED debt-free?
No. It carries net debt of ₹383 Cr.
How much does the VIVIMED LABS LIMITED share price move in a day?
On a typical session VIVIMED LABS LIMITED moves 2.68% — that is the median absolute close-to-close move across its last 185 trading days. Announcement days are routinely larger.
Where can I track VIVIMED LABS LIMITED's announcements?
Every NSE and BSE filing by VIVIMED LABS LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.